The device is approved for sale in the United States, Canada and more than 20 other countries.The tissue fluorescence visualization technology on which the VELscope is based was developed in partnership with the British Columbia Cancer Agency and is supported with more than $50 million in research provided by the National Institutes of Health and other leading institutions and universities.Demand